Dr. Bernd Liesenfeld
Dr. Liesenfeld joined Quick-Med in 2004 and led the development of the NIMBUS® technology used in the Bioguard line of products licensed to Derma Sciences. He has been involved in all aspects of commercializing Quick-Med's antimicrobial technologies, including biochemistry, biosafety, regulatory and production development. Dr. Liesenfeld also led the Quick-Med team that received the top industrial research prize at the 2011 Wound Healing Society meeting for U.S. Army-sponsored research that showed improved wound healing in an animal model of vesicant injury using an advanced multi-feature NIMBUS dressing. Dr. Liesenfeld received a Ph.D. in Materials Science and Engineering from the University of Florida and holds a Bachelor's degree in Mechanical Engineering and Management from the University of Vermont.
Chief Financial Officer
Mr. Jenssen has over 35 years of experience in strategic planning, process improvement, finance and accounting. He started his career at Deloitte Touche (1978-1984) before becoming Treasurer at Associated Press (1984-1998). In addition to working as a consultant since 1998, he was the CFO, COO and a Senior Managing Director at Rothschild North America investment bank (1998-2006). From 2006 until the present, Mr. Jenssen was the President of Jenssen Consulting, a business involved in providing strategic planning, process improvement, finance and accounting related services. Mr. Jenssen is a CPA, has an MBA from Columbia University in New York and has held several securities licenses.
Dr. William Toreki
Vice President, Research & Development
Dr. Toreki joined the Company in 2002 as QMT’s Chief Scientist and is the lead inventor on ten of the Company’s patents. Dr. Toreki received a Ph.D. in Polymer and Analytical Chemistry in 1988 from The University of Florida, and earned a Bachelor’s degree in Chemistry from The University of Delaware in 1982.
Dr. Toreki is an experienced inventor with 20 granted US patents to his credit, and during his tenure at QMT, he has been responsible for the development of three new antimicrobial platforms, including the adaptation of orphaned technology into the new Stay Fresh® antimicrobial system, the NIMBUS® antimicrobial technology that forms the core technology of the company, and the NimbuDerm™ antimicrobial skin protection formulation.